Nanogen Names Robert Saltmarsh Chief Financial Officer

Jan 07, 2005, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of advanced diagnostic products, announced today the appointment of
 Robert Saltmarsh as Chief Financial Officer.  Mr. Saltmarsh joined Nanogen as
 Vice President of Corporate Development last September.  In addition to
 participating in business development initiatives, he assumed oversight of all
 financial operations and investor relations for the company.
     Mr. Saltmarsh has over 25 years of experience in the high tech industry
 including public and private equity financing transactions, financial
 operations, and the building of successful finance functions.  He worked for
 Apple Computer, Inc. and Silicon Graphics, Inc. during times of tremendous
 growth.  At both companies, he was the Vice President of Finance and
 Treasurer.  Mr. Saltmarsh has also been Chief Financial Officer of Radius and  For the three years prior to joining Nanogen, he consulted for a
 series of start-up companies and taught entrepreneurial finance at the
 University of California at Riverside.  He received a B.A. in Economics and an
 M.B.A. in Finance from the University of Michigan.
     "Robert brings broad treasury and financial management skills to Nanogen,
 having successfully directed financings, M&A activity and administrative
 functions for evolving companies.  We're pleased he'll join Nanogen's
 executive team during a time marked by exciting growth," said Howard C.
 Birndorf, Nanogen Chairman and Chief Executive Officer.
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
 and broad suite of analyte specific reagents to develop tests to detect
 infectious diseases, drug toxicity and mutations associated with cancer,
 cardiovascular and genetic diseases.  The next generation instrument system,
 the NanoChip(R) 400, is expected to be available in 2005.  Nanogen's
 subsidiary SynX offers a line of point-of-care diagnostic tests and is
 building expertise in cardiac related health conditions.  Nanogen's ten years
 of pioneering research involving nanotechnology may also have future
 applications in medical diagnostics, biowarfare and other industries.  For
 additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof. Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.